These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 14668944)

  • 1. The potential role of antileukotriene drugs in atherosclerosis.
    Spanbroek R; Habenicht AJ
    Drug News Perspect; 2003 Oct; 16(8):485-9. PubMed ID: 14668944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis.
    Bäck M
    Curr Pharm Des; 2009; 15(27):3116-32. PubMed ID: 19754386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunopharmacological role of the leukotriene receptor antagonists and inhibitors of leukotrienes generating enzymes in multiple sclerosis.
    Mirshafiey A; Jadidi-Niaragh F
    Immunopharmacol Immunotoxicol; 2010 Jun; 32(2):219-27. PubMed ID: 20298145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Lipoxygenase: a target for antiinflammatory drugs revisited.
    Steinhilber D
    Curr Med Chem; 1999 Jan; 6(1):71-85. PubMed ID: 9873115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of leukotrienes and development of antileukotriene agents.
    Leff AR;
    Ann Allergy Asthma Immunol; 2001 Jun; 86(6 Suppl 1):4-8. PubMed ID: 11426915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential leukotriene receptor expression and calcium responses in endothelial cells and macrophages indicate 5-lipoxygenase-dependent circuits of inflammation and atherogenesis.
    Lötzer K; Spanbroek R; Hildner M; Urbach A; Heller R; Bretschneider E; Galczenski H; Evans JF; Habenicht AJ
    Arterioscler Thromb Vasc Biol; 2003 Aug; 23(8):e32-6. PubMed ID: 12816882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antileukotrienes and laboratory models of asthma.
    Lazarus SC
    Clin Rev Allergy Immunol; 1999; 17(1-2):223-33. PubMed ID: 10436868
    [No Abstract]   [Full Text] [Related]  

  • 8. The 5-lipoxygenase pathway in arterial wall biology and atherosclerosis.
    Lötzer K; Funk CD; Habenicht AJ
    Biochim Biophys Acta; 2005 Sep; 1736(1):30-7. PubMed ID: 16081317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antileukotriene drugs: clinical application, effectiveness and safety.
    Riccioni G; Bucciarelli T; Mancini B; Di Ilio C; D'Orazio N
    Curr Med Chem; 2007; 14(18):1966-77. PubMed ID: 17691939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in the management of asthma.
    Drazen JM
    Pharmacotherapy; 1997; 17(1 Pt 2):22S-30S. PubMed ID: 9017785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of leukotrienes in the management of asthma: biology and clinical therapy.
    Leff AR
    Annu Rev Med; 2001; 52():1-14. PubMed ID: 11160764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of leukotrienes and antileukotriene agents in the pathogenesis and treatment of allergic rhinitis.
    Simon RA
    Clin Rev Allergy Immunol; 1999; 17(1-2):271-5. PubMed ID: 10436872
    [No Abstract]   [Full Text] [Related]  

  • 13. Antileukotriene agents for the treatment of lung disease.
    Scott JP; Peters-Golden M
    Am J Respir Crit Care Med; 2013 Sep; 188(5):538-44. PubMed ID: 23822826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-Mediated Intracellular Donation of Nitric Oxide Potently Inhibits 5-Lipoxygenase: A Possible Key to Future Antileukotriene Therapy.
    Roos J; Peters M; Maucher IV; Kühn B; Fettel J; Hellmuth N; Brat C; Sommer B; Urbschat A; Piesche M; Vogel A; Proschak E; Blöcher R; Buscató E; Häfner AK; Matrone C; Werz O; Heidler J; Wittig I; Angioni C; Geisslinger G; Parnham MJ; Zacharowski K; Steinhilber D; Maier TJ
    Antioxid Redox Signal; 2018 May; 28(14):1265-1285. PubMed ID: 28699354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRP-187: A potent inhibitor of leukotriene biosynthesis that acts through impeding the dynamic 5-lipoxygenase/5-lipoxygenase-activating protein (FLAP) complex assembly.
    Garscha U; Voelker S; Pace S; Gerstmeier J; Emini B; Liening S; Rossi A; Weinigel C; Rummler S; Schubert US; Scriba GK; Çelikoğlu E; Çalışkan B; Banoglu E; Sautebin L; Werz O
    Biochem Pharmacol; 2016 Nov; 119():17-26. PubMed ID: 27592027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukotrienes and atherosclerosis.
    Riccioni G; Bäck M; Capra V
    Curr Drug Targets; 2010 Jul; 11(7):882-7. PubMed ID: 20388065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis.
    Spanbroek R; Grabner R; Lotzer K; Hildner M; Urbach A; Ruhling K; Moos MP; Kaiser B; Cohnert TU; Wahlers T; Zieske A; Plenz G; Robenek H; Salbach P; Kuhn H; Radmark O; Samuelsson B; Habenicht AJ
    Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1238-43. PubMed ID: 12552108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-Lipoxygenase: mechanisms of regulation.
    Rådmark O; Samuelsson B
    J Lipid Res; 2009 Apr; 50 Suppl(Suppl):S40-5. PubMed ID: 18987389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Modulation of leukotriene pathway - potential targets].
    Peter H; Lýdia B
    Ceska Slov Farm; 2012 Jun; 61(3):101-6. PubMed ID: 22913825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The putative role of leukotrienes in experimental atherogenesis.
    Jawień J
    Pol Arch Med Wewn; 2009; 119(1-2):90-3. PubMed ID: 19341185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.